ISIN:FR0013154002

Sartorius Stedim Biotech SA: Implementation of a new contract of liquidity with Kepler Cheuvreux

Mardi, mai 4, 2021 - 12:23pm

of the French Commercial Code, and the AMF decision no.

Key Points: 
  • of the French Commercial Code, and the AMF decision no.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

First-quarter results of Sartorius Stedim Biotech

Mercredi, avril 21, 2021 - 6:00am

(All figures in sales revenue growth in constant currencies)\nThe Sartorius Stedim Biotech Group has a very sound balance sheet and financial key figures.

Key Points: 
  • (All figures in sales revenue growth in constant currencies)\nThe Sartorius Stedim Biotech Group has a very sound balance sheet and financial key figures.
  • Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events.\nThis is a translation of the original French-language press release.
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation.
  • The original French press release is the legally binding version.\nFollow Sartorius Stedim Biotech on Twitter @Sartorius_Group and on LinkedIn.\nDr.

Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

Mercredi, mars 24, 2021 - 2:44pm

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.

Key Points: 
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically.
  • Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris.
  • With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.

Sartorius Stedim Biotech increases its full-year 2021 guidance

Jeudi, mars 18, 2021 - 7:13am

AUBAGNE, France, March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021.

Key Points: 
  • AUBAGNE, France, March 18, 2021 /PRNewswire/ -- Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021.
  • The major part of the expected additional business is related to the coronavirus pandemic as many products of Sartorius Stedim Biotech are used for manufacturing vaccines.
  • Sartorius Stedim Biotech will publish first quarter 2021 figures as scheduled on April 21, 2021.
  • Furthermore, Sartorius Stedim Biotech reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided.